TriangleNCT02722941 · OUTCOME
Complete Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
Complete Response (CR) rate to panobinostat maintenance therapy after autologous HCT. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow.
Groups in this outcome
Cohort A: Maintenance Therapy
Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
Cohort B: Maintenance Therapy
Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
| Group | Source count |
|---|---|
| Cohort A: Maintenance Therapy | 15 |
| Cohort B: Maintenance Therapy | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A: Maintenance Therapy | 73.33 | Not reported | 44.9 | 92.2 | Not reported |
| Cohort B: Maintenance Therapy | 66.6 | Not reported | 38.4 | 88.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 44.9
- upper Limit
- 92.2
- value
- 73.33
- group Id
- OG001
- lower Limit
- 38.4
- upper Limit
- 88.2
- value
- 66.6
- denoms
- counts
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 15
- units
- Participants
- description
- Complete Response (CR) rate to panobinostat maintenance therapy after autologous HCT. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
- id
- OG000
- title
- Cohort A: Maintenance Therapy
- description
- Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
- id
- OG001
- title
- Cohort B: Maintenance Therapy
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Complete Response Rate
- type
- SECONDARY
- unit Of Measure
- percentage
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice